A Phase 3 interventional study of Durvalumab and Cisplatin in Muscle Invasive Bladder Cancer, sponsored by AstraZeneca. Active, not recruiting at 188 sites in 22 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing durvalumab in Urinary Bladder Neoplasms — 4 open to participants now, 12 under way, 3 of them phase 3. durvalumab · Urinary Bladder Neoplasms.
Among the 19 studies testing durvalumab in Urinary Bladder Neoplasms, this one is the 2nd largest by enrollment, is one of 5 that started in 2018, is one of 3 in phase 3, reaches primary completion later than 0 of the 11 other live ones, and was the 7th registered.
1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.
Browse Urinary Bladder Neoplasms studies →4 of the 19 studies testing durvalumab in Urinary Bladder Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
H. Lee Moffitt Cancer Center and Research Institute · Sites in United States
Ages 18+
AstraZeneca · Sites in Australia, Brazil, Canada and 4 more countries
Ages 18+
Yuanquan Yang · Sites in United States
Ages 18+
AstraZeneca
Ages 18+
By country, each count listing its studies:
durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, durvalumab is the treatment under test here. Read study by study →
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 13 · Phase 3 3 · Phase 4 1
First in 2016; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,063 is above the median of 60 across 1,296 interventional studies indexed under Urinary Bladder Neoplasms.
Median enrollment 39 across the 19 interventional studies. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 19 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
20 studies in Urinary Bladder Neoplasms by AstraZeneca: 5 open now, 11 under way, 4 of them phase 3. Of 9 finished, 2 (22%) have results posted.
Among the 20 studies in Urinary Bladder Neoplasms by AstraZeneca, this one is the 2nd largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2018, is one of 4 in phase 3, reaches primary completion later than 2 of the 10 other live ones, and was the 9th registered.
AstraZeneca’s Urinary Bladder Neoplasms studies by the year they started, since 2003.
3 of the studies testing durvalumab in Urinary Bladder Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03601455Jonsson Comprehensive Cancer CenterRadiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer | 2027-01-31 |
| NCT03768570Canadian Cancer Trials GroupTrimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer | 2027-03-31 |
| NCT06263153Yuanquan YangFutibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 19 studies testing durvalumab in Urinary Bladder Neoplasms, from their registry updates:
Among AstraZeneca’s 20 in Urinary Bladder Neoplasms:
This tab as a report to print or save as PDF → With an account.
A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chemotherapy + Durvalumab
Drug: Durvalumab · Drug: Cisplatin · Drug: Gemcitabine
Chemotherapy alone
Drug: Cisplatin · Drug: Gemcitabine
Anti- PD-L1 Antibody
Chemotherapy Agent
Chemotherapy agent
Pathologic Complete Response (pCR) Rates at Time of Cystectomy
pCR rate is defined as the proportion of patients whose pathological staging was T0N0M0 as assessed per central pathology review using specimens obtained via radical cystectomy following the neoadjuvant treatment. The denominator for pCR will be the number of patients in the FAS.
Time frame: Up to 6 months
Event-free Survival (EFS) Per Central Review Defined as Time From Randomization to Event
EFS is defined as the time from randomization to the first recurrence of disease post radical cystectomy, time of first documented progression in patients who were medically precluded for radical cystectomy, or time of expected surgery in patients who refuse to undergo a radical cystectomy or failure to undergo a radical cystectomy in participants with residual disease, or the time of death due to any cause, whichever occurs first
Time frame: Up to 48 months
Event-free Survival at 24 Months (EFS24) Per Central Review Defined as Time From Randomization to Event
EFS24 is defined as the Kaplan-Meier estimate of EFS at 24 months after randomization, as assessed per blinded independent central review or by central pathology review if a biopsy is required for a suspected new lesion, and per local investigator or local biopsy review if a biopsy is required for a suspected new lesion
Time frame: Up to 24 months
Proportion of Patients Who Undergo Cystectomy
The proportion of patients who undergo cystectomy is defined as the proportion patients who undergo radical cystectomy after the neoadjuvant treatment. The denominator will be patients in the FAS.
Time frame: Up to 6 months
Overall Survival
OS is defined as the time from the date of randomization until death due to any cause regardless of whether the patient withdraws from randomized therapy or receives another anti-cancer therapy (i.e., date of death or censoring - date of randomization + 1)
Time frame: Up to 65 months
Metastasis-free Survival Per Investigator Assessment or Local Biopsy Review.
MFS is defined as the time from date of randomization until the first recognition of distant metastases or death, whichever occurs first
Time frame: Up to 48 months
Disease-specific Survival Per Investigator Assessment or Local Biopsy Review.
DSS is defined as the time from the date of randomization until death due to bladder cancer
Time frame: Up to 48 months
Immunogenicity of Durvalumab When Used in Combination With Gemcitabine/Cisplatin as Measured by Presence of Antidrug Antibodies (ADA)
Whole blood samples for assessing ADA for durvalumab in serum were collected from patients undergoing durvalumab treatment, following the specified assessment schedule. ADA prevalence is the proportion of patients with a positive ADA result at any time, baseline or post-baseline. Treatment-emergent ADA includes both treatment-induced and treatment-boosted ADA. Its incidence is the proportion of patients with treatment-emergent ADA positivity. Treatment-boosted ADA refers to a baseline-positive ADA titer that increased ≥4-fold during the study. Persistently positive patients have at least two post-baseline ADA-positive readings, with at least 16 weeks between the first and last, or an ADA-positive result at the final assessment. This includes baseline-positive patients meeting these criteria. Transiently positive is defined by at least one post-baseline ADA-positive reading without being persistently positive, including baseline-positive patients meeting these terms.
Time frame: Up to 12 months
Patients randomized to treatments Arm 1 or Arm 2, will be treated according to their renal function. Recruitment for borderline renal function patients will be limited to up to 20% of the targeted global population. Recruitment for patients with T2N0 disease will be limited to approximately 40% of the targeted global population; once the 40% cap has been reached, only T2-4N1M0 and T3-4N0M0 patients will be allowed to be enrolled onto the study. Completion status is reported by treatment phase
| Milestone | Durvalumab + Gemcitabine + Cisplatin | Gemcitabine + Cisplatin |
|---|---|---|
| Started | 533 | 530 |
| Started neoadjuvant treatment | 530 | 526 |
| Completed neoadjuvant treatment | 417 | 389 |
| Completed radical cystectomy | 469 | 441 |
| Started adjuvant treatment | 383 | 0 |
| Completed adjuvant treatment | 288 | 0 |
| Completed | 0 | 0 |
| Not completed | 533 | 530 |
| Withdrew: Terminated the study | 154 | 197 |
| Withdrew: Continuing study off treatment | 379 | 333 |
pCR rate is defined as the proportion of patients whose pathological staging was T0N0M0 as assessed per central pathology review using specimens obtained via radical cystectomy following the neoadjuvant treatment. The denominator for pCR will be the number of patients in the FAS.
| Participants | Durvalumab + Gemcitabine + Cisplatin | Gemcitabine + Cisplatin |
|---|---|---|
| Pathologic Complete Response (pCR) Rates at Time of Cystectomy | 199 | 146 |
EFS is defined as the time from randomization to the first recurrence of disease post radical cystectomy, time of first documented progression in patients who were medically precluded for radical cystectomy, or time of expected surgery in patients who refuse to undergo a radical cystectomy or failure to undergo a radical cystectomy in participants with residual disease, or the time of death due to any cause, whichever occurs first
| months | Durvalumab + Gemcitabine + Cisplatin | Gemcitabine + Cisplatin |
|---|---|---|
| Event-free Survival (EFS) Per Central Review Defined as Time From Randomization to Event | NA (13.4 to NA) | 46.1 (8.6 to NA) |
EFS24 is defined as the Kaplan-Meier estimate of EFS at 24 months after randomization, as assessed per blinded independent central review or by central pathology review if a biopsy is required for a suspected new lesion, and per local investigator or local biopsy review if a biopsy is required for a suspected new lesion
| Percentage of participants | Durvalumab + Gemcitabine + Cisplatin | Gemcitabine + Cisplatin |
|---|---|---|
| Event-free Survival at 24 Months (EFS24) Per Central Review Defined as Time From Randomization to Event | 67.8 (63.6 to 71.7) | 59.8 (55.4 to 64) |
The proportion of patients who undergo cystectomy is defined as the proportion patients who undergo radical cystectomy after the neoadjuvant treatment. The denominator will be patients in the FAS.
| Participants | Durvalumab + Gemcitabine + Cisplatin | Gemcitabine + Cisplatin |
|---|---|---|
| Proportion of Patients Who Undergo Cystectomy | 469 | 441 |
OS is defined as the time from the date of randomization until death due to any cause regardless of whether the patient withdraws from randomized therapy or receives another anti-cancer therapy (i.e., date of death or censoring - date of randomization + 1)
| Months | Durvalumab+Gemcitabine+Cisplatin | Gemcitabine+Cisplatin |
|---|---|---|
| Overall Survival | NA (41.9 to NA) | NA (24.1 to NA) |
MFS is defined as the time from date of randomization until the first recognition of distant metastases or death, whichever occurs first
| Months | Durvalumab + Gemcitabine + Cisplatin | Gemcitabine + Cisplatin |
|---|---|---|
| Metastasis-free Survival Per Investigator Assessment or Local Biopsy Review. | NA (24.2 to NA) | NA (15 to NA) |
DSS is defined as the time from the date of randomization until death due to bladder cancer
| months | Durvalumab + Gemcitabine + Cisplatin | Gemcitabine + Cisplatin |
|---|---|---|
| Disease-specific Survival Per Investigator Assessment or Local Biopsy Review. | NA (NA to NA) | NA (50.9 to NA) |
Whole blood samples for assessing ADA for durvalumab in serum were collected from patients undergoing durvalumab treatment, following the specified assessment schedule. ADA prevalence is the proportion of patients with a positive ADA result at any time, baseline or post-baseline. Treatment-emergent ADA includes both treatment-induced and treatment-boosted ADA. Its incidence is the proportion of patients with treatment-emergent ADA positivity. Treatment-boosted ADA refers to a baseline-positive ADA titer that increased ≥4-fold during the study. Persistently positive patients have at least two post-baseline ADA-positive readings, with at least 16 weeks between the first and last, or an ADA-positive result at the final assessment. This includes baseline-positive patients meeting these criteria. Transiently positive is defined by at least one post-baseline ADA-positive reading without being persistently positive, including baseline-positive patients meeting these terms.
| Participants | Durvalumab + Gemcitabine + Cisplatin |
|---|---|
| ADA positive at any visit (ADA prevalence) | 37 |
| Treatment-emergent ADA positive (ADA Incidence) | 8 |
| Treatment-boosted ADA | 1 |
| Treatment-induced ADA (Positive Post-baseline only) | 7 |
| ADA Positive at Baseline only | 29 |
| ADA Positive Post-baseline and Positive at Baseline | 1 |
| Persistently Positive | 4 |
| Transiently Positive | 4 |
| nAb Positive at any visit | 6 |
Collected over Includes AEs between date of first dose and the earliest of: maximum date of (last dose or surgery) + 90days, date of first dose of subsequent anti-cancer therapy. Total follow up about 2 years. The frequency assessment was: Neoadjuvant, every 3 weeks, Post Surgery, every week, Adjuvant and Follow Up: every 4 weeks. All-cause mortality (death due to any cause): from randomization up to EFS IA2 DCO (April 29, 2024). Maximum timeframe of approximately 5.4 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Durvalumab + Gemcitabine + Cisplatin | 27/533 (5.1%) | 326/530 (61.5%) | 522/530 (98.5%) |
| Gemcitabine + Cisplatin | 29/526 (5.5%) | 287/526 (54.6%) | 511/526 (97.1%) |
| Event | Durvalumab + Gemcitabine + Cisplatin | Gemcitabine + Cisplatin |
|---|---|---|
| Urinary tract infectionInfections and infestations | 59/530 | 69/526 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 35/530 | 27/526 |
| Acute kidney injuryRenal and urinary disorders | 25/530 | 24/526 |
| PyelonephritisInfections and infestations | 19/530 | 23/526 |
| Prostate cancer stage iiNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 21/530 | 10/526 |
| UrosepsisInfections and infestations | 20/530 | 10/526 |
| SepsisInfections and infestations | 19/530 | 14/526 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 18/530 | 5/526 |
| AnaemiaBlood and lymphatic system disorders | 5/530 | 17/526 |
| HydronephrosisRenal and urinary disorders | 15/530 | 8/526 |
| Event | Durvalumab + Gemcitabine + Cisplatin | Gemcitabine + Cisplatin |
|---|---|---|
| NauseaGastrointestinal disorders | 281/530 | 254/526 |
| ConstipationGastrointestinal disorders | 204/530 | 201/526 |
| AnaemiaBlood and lymphatic system disorders | 200/530 | 200/526 |
| FatigueGeneral disorders | 190/530 | 169/526 |
| NeutropeniaBlood and lymphatic system disorders | 136/530 | 163/526 |
| Decreased appetiteMetabolism and nutrition disorders | 140/530 | 131/526 |
| Urinary tract infectionInfections and infestations | 124/530 | 108/526 |
| PyrexiaGeneral disorders | 107/530 | 84/526 |
| DiarrhoeaGastrointestinal disorders | 106/530 | 74/526 |
| VomitingGastrointestinal disorders | 101/530 | 96/526 |
The Full analysis set (FAS) included all randomized participants.
| Age, Continuous(Years) | Durvalumab + Gemcitabine + Cisplatin | Gemcitabine + Cisplatin | Total |
|---|---|---|---|
| Mean | 64.1 ± 8.9 | 64.6 ± 8.9 | 64.4 ± 8.9 |
| Sex: Female, Male(Participants) | Durvalumab + Gemcitabine + Cisplatin | Gemcitabine + Cisplatin | Total |
|---|---|---|---|
| Female | 96 | 97 | 193 |
| Male | 437 | 433 | 870 |
| Race/Ethnicity, Customized(Participants) | Durvalumab + Gemcitabine + Cisplatin | Gemcitabine + Cisplatin | Total |
|---|---|---|---|
| HISPANIC OR LATINO | 44 | 41 | 85 |
| MISSING | 6 | 12 | 18 |
| NOT HISPANIC OR LATINO | 483 | 477 | 960 |
| Race/Ethnicity, Customized(Participants) | Durvalumab + Gemcitabine + Cisplatin | Gemcitabine + Cisplatin | Total |
|---|---|---|---|
| ASIAN | 152 | 145 | 297 |
| BLACK OR AFRICAN AMERICAN | 6 | 4 | 10 |
| MISSING | 14 | 22 | 36 |
| OTHER | 7 | 1 | 8 |
| WHITE | 354 | 358 | 712 |
Showing the first 100 of 188 sites across 22 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Nov 2018 to primary completion in Apr 2024, 65 months.
Results were first posted in Jul 2025, 1 year 2 months after primary completion.
Of 39 industry-sponsored phase 3 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 74. This study's 65 months is above that.
Counting every sponsor, half of 73 studies reached it within 65 months; a quarter within 40 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Durvalumab